@article {Mart{\'\i}nez1765, author = {Daniel Mart{\'\i}nez and Jes{\'u}s Sancho and Emilio Servera and Julio Mar{\'\i}n}, title = {Tolerance of Volume Control Noninvasive Ventilation in Subjects With Amyotrophic Lateral Sclerosis}, volume = {60}, number = {12}, pages = {1765--1771}, year = {2015}, doi = {10.4187/respcare.04172}, publisher = {Respiratory Care}, abstract = {BACKGROUND: Noninvasive ventilation (NIV) tolerance has been identified as an independent predictor of survival in amyotrophic lateral sclerosis (ALS). Volume control continuous mandatory ventilation (VC-CMV) NIV has been associated with poor tolerance. The aim of this study was to determine the tolerance of subjects with ALS to VC-CMV NIV.METHODS: This was a prospective study involving subjects with ALS who were treated with VC-CMV NIV. Respiratory and functional parameters were recorded when the subjects began ventilatory support. NIV tolerance was evaluated after 3 months.RESULTS: Eighty-seven subjects with ALS were included. After 3 months, 80 subjects (92\%) remained tolerant of NIV. Tolerant subjects presented greater survival (median 22.0 months, 95\% CI 14.78{\textendash}29.21) than intolerant subjects (median 6.0 months, 95\% CI 0.86{\textendash}11.13) (P = .03). The variables that best predicted NIV tolerance were mechanically assisted cough peak flow (P = .01) and percentage of time spent with SpO2 \< 90\% at night while on NIV (P = .03)CONCLUSIONS: VC-CMV NIV provides high rates of NIV tolerance in subjects with ALS. Mechanically assisted cough peak flow and percentage of time spent with SpO2 \< 90\% at night while using NIV are the 2 factors associated with tolerance of VC-CMV NIV in subjects with ALS.}, issn = {0020-1324}, URL = {https://rc.rcjournal.com/content/60/12/1765}, eprint = {https://rc.rcjournal.com/content/60/12/1765.full.pdf}, journal = {Respiratory Care} }